Compare RC & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RC | KROS |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.6M | 222.7M |
| IPO Year | 2011 | 2020 |
| Metric | RC | KROS |
|---|---|---|
| Price | $1.10 | $10.77 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 7 |
| Target Price | $1.50 | ★ $19.83 |
| AVG Volume (30 Days) | ★ 1.7M | 169.6K |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.57% | N/A |
| EPS Growth | 45.25 | ★ 146.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.06 | $9.69 |
| 52 Week High | $3.26 | $22.55 |
| Indicator | RC | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 35.65 | 42.58 |
| Support Level | $1.08 | $10.65 |
| Resistance Level | $1.88 | $11.86 |
| Average True Range (ATR) | 0.08 | 0.50 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 22.41 | 6.92 |
Ready Capital Corp is a real estate finance company that originates, acquires, finances, and services LMM loans, SBA loans, construction loans, USDA loans and, to a lesser extent, MBS collateralized mainly by LMM loans or other real estate-related investments. Its loans are used by businesses to purchase real estate used in their operations or by investors seeking to acquire multi-family, office, retail, mixed use or warehouse properties. It operates through two segments: LMM Commercial Real Estate, which originates LMM loans across the life-cycle of an LMM property including construction, bridge, stabilized and agency loan channels, and Small Business Lending, which acquires, originates and services owner-occupied loans guaranteed by the SBA and also originates and services USDA loans.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.